Latest Reproductive Health News

Page 1 of 1
Revvity has set out a long-range growth strategy built around AI-enabled scientific discovery, recurring software revenue and specialised diagnostics. The plan includes double-digit adjusted EPS growth, margin expansion and about US$5 billion of capital capacity through 2031, but formal 2027 guidance is still pending.
Ada Torres
Ada Torres
14 Nov 2026
Monash IVF Group’s underlying NPAT fell 41% to A$16.1 million in FY26, missing its recently reduced guidance as softer Australian IVF activity outweighed international growth. A second-half market-share recovery, lower planned capital spending and a new productivity program now carry the FY27 investment case.
Ada Torres
Ada Torres
23 Oct 2026
Memphasys has reported record September-quarter invoiced revenue of A$211,000 as its Felix fertility device moves into more international markets. The commercial progress comes alongside A$3.5 million in funding, but the loan still requires shareholder approval for conversion into notes.
Ada Torres
Ada Torres
13 Oct 2026
Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.
Ada Torres
Ada Torres
20 Aug 2026
Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.
Ada Torres
Ada Torres
1 June 2026
EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.
Ada Torres
Ada Torres
1 Oct 2025
EVE Health Group has appointed Dr Fiona Cousins as the inaugural member of its Scientific Advisory Board, reinforcing its commitment to advancing treatments for dysmenorrhoea and endometriosis ahead of the commercial launch of Dyspro™.
Ada Torres
Ada Torres
15 Sept 2025
Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.
Ada Torres
Ada Torres
23 Jan 2025
Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.
Ada Torres
Ada Torres
16 Jan 2025

Browse the archive

Full archive